Medicina
Departamento
University of the Witwatersrand
Johannesburgo, SudáfricaPublicacións en colaboración con investigadores/as de University of the Witwatersrand (29)
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people ≥65 years of age
HIV Medicine, Vol. 24, Núm. 1, pp. 27-36
2022
2021
-
Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
Infectious Diseases and Therapy, Vol. 10, Núm. 2, pp. 775-788
2020
-
Impact of Comorbidity on Physical Function in Patients With Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics: Results From a Cross-Sectional Study
Arthritis Care and Research, Vol. 72, Núm. 6, pp. 822-828
-
Influence of MUC5B gene on antisynthetase syndrome
Scientific Reports, Vol. 10, Núm. 1
-
Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia
American Journal of Transplantation, Vol. 20, Núm. 6, pp. 1629-1641
-
The rate of bone loss slows after 1–2 years of initial antiretroviral therapy: final results of the Strategic Timing of Antiretroviral Therapy (START) bone mineral density substudy
HIV Medicine, Vol. 21, Núm. 1, pp. 64-70
2019
-
An international perspective on hospitalized patients with viral community-acquired pneumonia
European Journal of Internal Medicine, Vol. 60, pp. 54-70
-
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
The Lancet HIV, Vol. 6, Núm. 10, pp. e655-e666
-
Differences associated with age at onset in early systemic sclerosis patients: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR) database
Scandinavian Journal of Rheumatology, Vol. 48, Núm. 1, pp. 42-51
-
Hyperlipoproteinaemia(a) in patients with spondyloarthritis: results of the Cardiovascular in Rheumatology (CARMA) project
Clinical and experimental rheumatology, Vol. 37, Núm. 5, pp. 774-782
-
Identification of a 3′-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study
Arthritis and Rheumatology, Vol. 71, Núm. 3, pp. 351-360
-
International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia
Journal of Infection, Vol. 79, Núm. 4, pp. 300-311
-
Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: A European Scleroderma Trials and Research (EUSTAR) analysis
Annals of the Rheumatic Diseases, Vol. 78, Núm. 9, pp. 1242-1248
-
Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the european scleroderma trials and research (eustar) cohort
Annals of the Rheumatic Diseases, Vol. 78, Núm. 5, pp. 648-656
2018
-
Gender differences in early systemic sclerosis patients: A report from the EULAR scleroderma trials and research group (EUSTAR) database
Clinical and Experimental Rheumatology, Vol. 36, pp. S68-S75
-
Microbiological testing of adults hospitalised with community-acquired pneumonia: An international study
ERJ Open Research, Vol. 4, Núm. 4
2017
-
Cardiovascular efficacy and safety of bococizumab in high-risk patients
New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539
-
Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis
Clinical and Experimental Rheumatology, Vol. 35, pp. S114-S121